1601 TRAPELO ROAD, WALTHAM, MA
Investor Presentation
Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
Invivyd, Inc. Elects New Directors at Annual Meeting of Stockholders
Reports First Quarter 2026 Financial Results and Recent Business Highlights
REVOLUTION Program & Measles April 9, 2026
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Free Writing Prospectus